In patients with resected non-metastatic melanoma, the liquid biopsy for the assessment of molecular residual disease (MRD) by circulating tumour DNA (ctDNA) represents a promising tool to stratify the risk and to monitor tumour evolution. However, its validation requires the demonstration of analytical validity, clinical validity and utility. Indeed, the development of sensitive and specific assays can optimize prognostication and eventually help clinicians to modulate adjuvant treatments, in order to improve clinical outcomes. Data about ctDNA-guided prognosis stratification is emerging, but clinical trials assessing ctDNA-guided therapeutic decisions are still ongoing. This review aims to depict the role of ctDNA-based MRD assessment in patients with non-metastatic melanoma and to provide a roadmap to face challenges for its introduction into clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctrv.2024.102788 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nuclear receptor PPARγ targets GPNMB to promote oligodendrocyte development and remyelination.
Brain
January 2025
Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry (Shaanxi Normal University), The Ministry of Education; College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Myelin injury occurs in brain ageing and in several neurological diseases. Failure of spontaneous remyelination is attributable to insufficient differentiation of oligodendrocyte precursor cells (OPCs) into mature myelin-forming oligodendrocytes in CNS demyelinated lesions. Emerging evidence suggests that peroxisome proliferator-activated receptor γ (PPARγ) is the master gatekeeper of CNS injury and repair and plays an important regulatory role in various neurodegenerative diseases.
View Article and Find Full Text PDFIs S100B protein useful in the follow up of non-metastatic cutaneous melanoma patients? A real-world cohort study.
Actas Dermosifiliogr
December 2024
Dermatology Department, Hospital Universitario de la Princesa, Madrid, Spain.
Background: This study evaluated the quality of cancer recurrence data in the National Cancer Database (NCDB) to determine if missingness and reporting consistency have improved enough to support national research.
Methods: This multi-methods study included NCDB analyses and a cancer registry staff survey. Trends in recurrence data missingness from 2004 to 2021 and multivariable analyses of factors associated with missingness from 2017 to 2021 were evaluated for 4,568,927 patients with non-metastatic cancer.
Neuroinflammation and glycosylation-related cerebrospinal fluid proteins for predicting functional decline in amyotrophic lateral sclerosis: a proteomic study.
Front Neurol
November 2024
Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Background: The rate of disease progression varies widely among patients with amyotrophic lateral sclerosis (ALS). Prognostic assessment using biomarkers is highly anticipated to improve clinical trial design. We aimed to explore the cerebrospinal fluid (CSF) for prognostic biomarkers to predict future functional decline in patients with ALS.
View Article and Find Full Text PDFModernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.
Invest New Drugs
December 2024
Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud- IUCT-O, 1 Avenue Irène Joliot-Curie, Toulouse, Cedex 9, 31059, France.
Article Synopsis
- * It introduces modern analysis techniques that factor in the timing and recurrence of immune-related AEs (irAEs) in cancer patients treated with immune checkpoint inhibitors, based on the MOTIVATE prospective study findings.
- * Results showed variations in the prevalence and timing of irAEs between melanoma and non-small cell lung cancer (NSCLC) patients, leading to more comprehensive safety assessments that can guide clinical and regulatory decisions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!